Compare · CDW vs WGS
CDW vs WGS
Side-by-side comparison of CDW Corporation (CDW) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDW and WGS operate in Retail: Computer Software & Peripheral Equipment (Technology), so they compete in similar markets.
- CDW is the larger of the two at $18.28B, about 6.1x WGS ($3.02B).
- CDW has been more active in the news (19 items in the past 4 weeks vs 9 for WGS).
- CDW has more recent analyst coverage (25 ratings vs 8 for WGS).
- Company
- CDW Corporation
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $18.28B
- $3.02B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Retail: Computer Software & Peripheral Equipment
- Retail: Computer Software & Peripheral Equipment
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2020
- News (4w)
- 19
- 9
- Recent ratings
- 25
- 8
CDW Corporation
CDW Corporation provides integrated information technology (IT) solutions to business, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. It operates through three segments: Corporate, Small Business, and Public. The company offers discrete hardware and software products, as well as integrated IT solutions, including on-premise, hybrid and cloud capabilities across data center and networking, digital workspace, security, and virtualization. Its hardware products comprise notebooks/mobile devices, network communications, desktop computers, video monitors, enterprise and data storage, and other hardware; and software products include application suites, security, virtualization, operating systems, and network management. The company also provides field services, managed services, warranties, configuration services, partner services, and telecom services. CDW Corporation was founded in 1984 and is based in Lincolnshire, Illinois.
Latest CDW
- CDW Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 8-K filed by CDW Corporation
- SEC Form FWP filed by CDW Corporation
- Director Nelms David W was granted 148 shares, increasing direct ownership by 0.29% to 51,563 units (SEC Form 4)
- Director Jones Marc Ellis was granted 20 shares, increasing direct ownership by 0.44% to 4,533 units (SEC Form 4)
- Director Addicott Virginia C. was granted 82 shares, increasing direct ownership by 0.44% to 18,675 units (SEC Form 4)
- Officer Kumar Mukesh was granted 192 shares, increasing direct ownership by 0.94% to 20,723 units (SEC Form 4)
- Officer Sanderson Katherine Elizabeth was granted 243 shares, increasing direct ownership by 0.99% to 24,743 units (SEC Form 4)
- Officer Kulevich Frederick J. was granted 185 shares, increasing direct ownership by 0.41% to 44,825 units (SEC Form 4)
- Director Foxx Anthony R was granted 30 shares, increasing direct ownership by 0.44% to 6,758 units (SEC Form 4)
Latest WGS
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 6,547 shares and sold $310,932 worth of shares (3,692 units at $84.22), increasing direct ownership by 3% to 107,227 units (SEC Form 4) to cover taxes
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 2,462 shares and sold $108,220 worth of shares (1,285 units at $84.22), increasing direct ownership by 3% to 41,476 units (SEC Form 4) to satisfy tax liability
- GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $31,188 worth of shares (372 units at $83.84), increasing direct ownership by 0.86% to 40,299 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by GeneDx Holdings Corp.
- GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
- GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s